immunostimulator/neoplasms

FIELD OF THE INVENTION The present invention relates to the field of immune-based therapeutic agents for cancer. BACKGROUND The Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) is a variable RNA binding peptide of 86 to 110 amino acids in length that is encoded on two

FIELD OF THE INVENTION The present invention relates to the field of immune-based therapeutic agents for cancer. BACKGROUND The Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) is a variable RNA binding peptide of 86 to 110 amino acids in length that is encoded on two

FIELD OF THE INVENTION The present invention relates to the field of immune-based therapeutic agents for cancer. BACKGROUND Immune checkpoints represent inhibitory molecules that result in the inhibition of an effective immune response towards cancer which can result in tumor evasion. Immune

FIELD OF THE INVENTION The present invention relates to the field of immune-based therapeutic agents for cancer. BACKGROUND Immune checkpoints represent inhibitory molecules that result in the inhibition of an effective immune response towards cancer which can result in tumor evasion. Immune

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. National Stage of International Application No. PCT/JP2005/000238, filed Jan. 12, 2005, which, in turn, claims the benefit of Japanese Patent Application No. 2004-005186, filed Jan. 13, 2004. TECHNICAL FIELD The present invention

FIELD OF THE INVENTION The invention relates generally to an immunostimulator of all animals and humans, feed, veterinary pharmaceuticals, beverages, food, health food, and pharmaceuticals containing said immunostimulator, infectious diseases that are subject for administration of said

FIELD OF THE INVENTION The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least one unmethylated CpG dinucleotide which are immunostimulatory. BACKGROUND OF THE INVENTION In the 1970s, several investigators

FIELD OF THE INVENTION The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least one unmethylated CpG dinucleotide which are immunostimulatory. BACKGROUND OF THE INVENTION In the 1970s, several investigators

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 1, 2013, is named 067802.sub.13CU14.sub.13 US2_Sequence_isting.txt and is 77,865 bytes in size. The

FIELD OF THE INVENTION This invention, in the field of molecular biology, immunology and medicine, relates to a polypeptide vaccine, produced in plants, for inducing an immune response to a self-antigen (which is normally clonally expressed) on the surface of certain tumor cells. In a preferred

FIELD OF THE INVENTION The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. BACKGROUND OF THE INVENTION Bacterial DNA has immune stimulatory effects to activate B cells and natural killer cells, but

FIELD OF THE INVENTION The invention relates generally to the field of immunology, and more particularly to immunostimulatory molecules. More specifically the invention relates to ribonucleic acid (RNA) molecules, including oligoribonucleotides, with immunostimulatory activity. BACKGROUND OF THE

FIELD OF THE INVENTION The invention relates generally to the field of immunology, and more particularly to immunostimulatory molecules. More specifically the invention relates to ribonucleic acid (RNA) molecules, including oligoribonucleotides, with immunostimulatory activity. BACKGROUND OF THE

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The content of the electronically submitted substitute sequence listing, file name: 1700.sub.--0220004SEQ IDListing.ascii.txt; Size: 151,531 bytes; and Date of Creation: Jun. 22, 2012, filed herewith, is incorporated herein by reference in its

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The content of the electronically submitted sequence listing Name: 1700_0220004_RevisedListing_ascii.txt; Size 152,065 bytes; and Date of Creation: Aug. 10, 2012) filed herewith, is incorporated herein by reference in its entirety. BACKGROUND OF